摘要
目的研究格列齐特缓释片和瑞格列奈治疗2型糖尿病(T2DM)的疗效和安全性。方法按照WHO于1999年制订的糖尿病诊断标准,选择该院门诊T2DM患者共41例,随机分为2组,一组给予格列齐特缓释片60～120毫克/次每日1次,另一组给予瑞格列奈0.5～4.0毫克/次每日3次(三餐前15min),治疗24周后测定患者空腹血糖(FPG)、OGTT 2h血糖水平(OGTT 2hPG)、糖化血红蛋白(HbA1c)、空腹胰岛素水平(FINS)、OGTT 2h胰岛素水平(2hINS)、血脂、肝功能、肾功能以评估疗效与安全性。结果两组患者治疗前后FPG、OGTT 2hPG及HbA1c均降低,FINS、2hINS均增加,差异有统计学意义(P<0.05);其中格列齐特缓释片组FPG显著低于瑞格列奈组患者,瑞格列奈组患者HbA1c、不良反应发生率显著低于格列齐特缓释片组(P<0.05)。结论瑞格列奈治疗T2DM患者的疗效优于格列齐特缓释片,安全性更佳。
Objective To study the efficacy and safety of gliclazide modified release and repaglinide to treat type 2 diabetes. Methods According to the diabetes diagnosis standard established by WHO in 1999,divided 41 patients into two groups randomly.One group gave gliclazide modified release 60-120 mg/time once a day,the other one gave repaglinide 0.5-4.0 mg/time three times a day.Assessing the efficacy and safety by measuring patients′ FPG,OGTT 2 h PG,HbA1c,FINS,2 h INS,blood fat and the functions of liver and kidney after 24 weeks. Results The FPG,OGTT 2 h PG and HbA1c decreased,the FINS and 2 h INS increased in both groups after treatment,and there was a statistical significant （ P 〈0.05）.Patients′ FPG in Gliclazide modified release group was significantly lower than the repaglinide group.Patients′HbA1c and adverse effects rate in the repaglinide group were significantly lower than the gliclazide modified release group（ P 〈0.05）. Conclusion The efficacy and safety of repaglinide were better than gliclazide modified release （ P 〈0.05）in treatment of type 2 diabetes.
作者
刘娇
胡蕖
向腾霄
桂灵升
冉柳
邓娟
LIU Jiao;HU Qu;XIANG Tengxiao;GUI Lingsheng;RAN Liu;DENG Juan(Department of Endocrinology,Changshou District People＇s Hospital of Chongqing,Chongqing 401220,China)
出处
《检验医学与临床》
CAS
2018年第22期3405-3407,共3页
Laboratory Medicine and Clinic
关键词
瑞格列奈
格列齐特缓释片
2型糖尿病
临床疗效
安全性
repaglinide
gliclazide modified release
type 2 diabetes
therapeutic efficacy
safety
